OTC : BVNRY

Bavarian Nordic A/S

$8.76 USD

-$0.15 (-1.68%)

Volume
121
Average Volume
3.58K
Market Capitalization
$2.03B
P/E Ratio
11.95
Dividend Yield
0.00%
Price Target
Year High
$13.00
Year Low
$8.67
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$6.47
Company Overview

OTC

Paul John Chaplin

Biotechnology

Healthcare

BVNRY

1861

DK

USD

https://www.bavarian-nordic.com

45 33 26 83 83

071771109

N/A

Liquidity Metrics

0.01

6.47

3.58

0.75

0.00

Sales & Valuation

$5.93B

2.23

1.06

9.59

5.94

Profitability

$5.66

$1.32B

19.83%

26.95%

9.25%

8.32%

P/E Metrics

11.95

-0.93

-0.93

Analyst Price Target & Rating

Buy

4/5

1 Analysts

%

Financial Health Scores

7.99

7/9

$5.05B

$14.12B

$1.42B

$1.52B

Key Metrics (TTM)

$12.64B

2.14

5.63

6.47

9.25%

8.35%

8.72%

10.42%

$237.27

326 days

Company Executives
Name Title
Russell Thirsk Executive Vice President & Chief Operating Officer
Rolf Sass Sørensen Vice President of Investor Relations
Henrik Juuel Chief Financial Officer & Executive Vice President
Jean-Christophe May Executive Vice President & Chief Commercial Officer
Paul John Chaplin Chief Executive Officer & President
Nicole Seroff Vice President Corporate Communications
Poll Results

No votes yet today — be the first to share your view!

About Bavarian Nordic A/S (OTC:BVNRY) Stock

Bavarian Nordic A/S is a Danish biopharmaceutical company specializing in the development, production, and global commercialization of essential, life-saving vaccines. Its marketed portfolio includes non-replicating vaccines for smallpox and monkeypox (known as IMVAMUNE, IMVANEX, and JYNNEOS), as well as human rabies protection (Rabipur/RabAvert), a tick-borne encephalitis vaccine (Encepur), and an Ebola vaccine (MVABEA). The company also boasts a robust pipeline of investigational therapies. Notably, MVA-BN (freeze-dried) has concluded Phase III trials for smallpox, and MVA-BN RSV is currently in Phase III clinical development for respiratory syncytial virus (RSV). Additionally, ABNCoV2, a candidate for SARS-CoV-2, successfully completed its Phase II clinical trial, and TAEK-VAC is advanc ... ing through Phase I/II studies for select advanced HER2 and brachyury-expressing cancers. Bavarian Nordic maintains strategic alliances, including a licensing and collaboration agreement with AdaptVac, alongside further licensing arrangements with the National Cancer Institute and the Public Health Service. Its commercial operations and presence span numerous countries, such as the United States, Belgium, Germany, the Netherlands, Sweden, Switzerland, Austria, the United Kingdom, and Japan, reflecting a broad international footprint. Established in 1992, Bavarian Nordic A/S is headquartered in Hellerup, Denmark.

Bavarian Nordic A/S (BVNRY) Q1 2026 Earnings Call Transcript

2026-05-13 10:50:46

Bavarian Nordic A/S (BVNRY) Q1 2026 Earnings Call Transcript

Denmark's Bavarian Nordic raises 2026 forecast

2026-05-11 12:53:06

Denmark's Bavarian Nordic on ​Monday raised its ‌revenue guidance for 2026 ​to 5.5 ​billion - 5.7 billion Danish ⁠crowns ($866.93 million-$898.46 ​million).

Frequently Asked Questions

What is the current Bavarian Nordic A/S (BVNRY) stock price?

Bavarian Nordic A/S(OTC:BVNRY) stock price is $8.76 in the last trading session. During the trading session, BVNRY stock reached the peak price of $13 while $8.67 was the lowest point it dropped to. The percentage change in BVNRY stock occurred in the recent session was --1.68% while the dollar amount for the price change in BVNRY stock was -$0.15.

BVNRY's industry and sector of operation?

The OTC listed BVNRY is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of BVNRY?

Russell Thirsk | Executive Vice President & Chief Operating Officer
Rolf Sass Sørensen | Vice President of Investor Relations
Henrik Juuel | Chief Financial Officer & Executive Vice President
Jean-Christophe May | Executive Vice President & Chief Commercial Officer
Paul John Chaplin | Chief Executive Officer & President

How many employees does BVNRY have?

Number of BVNRY employees currently stands at 1861. BVNRY operates from Philip Heymans Alle 3, Hellerup, CR 2900, DK.

Link for BVNRY official website?

Official Website of BVNRY is: https://www.bavarian-nordic.com

How do I contact BVNRY?

BVNRY could be contacted at phone #45 33 26 83 83 and can also be accessed through its website. BVNRY operates from Philip Heymans Alle 3, Hellerup, CR 2900, DK.

How many shares of BVNRY are traded daily?

The average number of BVNRY shares traded daily for last 3 months was 3.58K.

What is the market cap of BVNRY currently?

The market value of BVNRY currently stands at $2.03B with its latest stock price at $8.76